Scientific scope and capacities.
EATRIS-CZ connects radiochemistry/radiopharmacy, molecular imaging and advanced microscopy to enable tracer development, in vivo validation and theranostic strategies. This platform supports translational decision-making by linking molecular findings to functional and spatial readouts (target engagement, biodistribution, pharmacodynamics, mechanism-linked phenotypes) and by providing imaging endpoints for preclinical and early clinical studies.
Main services to users (examples).
- Radiochemistry and tracer preparation workflows and radiolabeling support (design–synthesis–QC);
- Preclinical imaging studies (e.g., SPECT/CT-based workflows) including longitudinal monitoring and quantitative evaluation;
- Imaging biomarker development and radiomics-ready data generation with controlled metadata and analysis pipelines;
- High-resolution microscopy services supporting spatial validation in tissues and advanced cellular models.
Technology basis strengthened in 2020–2024.
New SPECT/CT and Mediso systems, together with confocal microscopy and Sigma 360 electron microscopy, expanded the node’s ability to bridge in vitro biology with in vivo relevance and strengthened iterative tracer development and evaluation.
The EATRIS Imaging and Tracing Platform provides a single point of entry to high-end expertise and cutting-edge translational imaging facilities, defragmenting the scattered nature of technical know-how and making optimal use of resources to improve R&D output.
EATRIS-CZ participation
- IMTM, NPI
Major technologies/infrastructures
- cyclotrons, in vivo imaging, animal facility, (GMP) production plants for tracers, radiochemistry.